WhichPeps

GHRP-6

Growth-hormone secretagogue hexapeptide

GH-axis physiology
Generic peptide vial illustrationGHRP-6
Evidence levelLimited human
Human evidenceLimited
Regulatory statusNot FDA-approved

What you need to know in 20 seconds

What is it?Growth-hormone secretagogue hexapeptide
Research focusGH-axis physiology
Human evidenceSmall human studies characterize exposure and show route-dependent GH, ACTH/cortisol and sleep effects.
Regulatory statusNot FDA-approved; FDA highlights compounding safety uncertainty.
Main limitationsPerformance, body-composition, recovery, sleep-treatment or longevity benefit.
SafetyFDA notes limited safety information and concerns including cortisol effects and increased blood glucose through reduced insulin sensitivity.
i
Small human studies characterize exposure and show route-dependent GH, ACTH/cortisol and sleep effects.

What the evidence actually supports

  • ✓Classify this as human pharmacology, not demonstrated lifestyle efficacy.
  • ✓Counterweight to simplistic better-sleep/recovery claims.
  • ✓Useful route/formulation caveat.

What is not established / key limitations

  • ×No established clinical evidence of better muscle gain, recovery, performance or longevity.
  • ×No evidence of a durable insomnia/recovery benefit.
  • ×No clinical-outcome benefit established for any tested route.

Selected study & evidence records

Human pharmacokinetics of GHRP-6

2012 · Healthy-volunteer pharmacokinetic study · n=9

Human exposure and pharmacokinetics were characterized across three IV dose levels.

Study detail → Primary source ↗

GHRP-6 stimulates sleep, GH, ACTH and cortisol release in normal men

1995 · Placebo-controlled sleep/endocrine physiology study · n=Small study

GHRP-6 increased GH, ACTH, cortisol and stage-2 sleep; slow-wave sleep was unchanged.

Study detail → Primary source ↗

Route-dependent sleep/endocrine effects of GHRP-6

1999 · Placebo-controlled route-comparison physiology study · n=Small study

Oral dosing did not change GH/ACTH/cortisol; intranasal dosing increased GH and showed route-dependent endocrine/sleep effects.

Study detail → Primary source ↗

Safety and unknowns

FDA notes limited safety information and concerns including cortisol effects and increased blood glucose through reduced insulin sensitivity.

Endocrine/appetite effects and long-term safety are incompletely characterized; unapproved product quality remains a separate concern.

Technical details

Mechanism / biologyGhrelin/GHS-receptor agonist that stimulates GH and can influence appetite/endocrine signalling.
Route / formulation boundaryPharmacokinetic and hormone responses do not establish clinical benefit.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. Published human PK regimen. See dosing_evidence records for route, regimen, population, duration and source.
Identifiers & alternate namesGHRP6 · GHRP 6

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.